Wellbeing Digital Sciences Inc. Stock Price, News & Analysis

Ketamine One has entered an exclusive two-year agreement with OVR Technology to implement a VR platform that enhances psychedelic treatments through olfactory experiences. The INHALE Wellness Platform aims to deepen patient immersion, promote relaxation, and improve outcomes in treatments involving ketamine, psilocybin, DMT, and MDMA.

This collaboration allows Ketamine One to leverage innovative scent technology to optimize therapeutic settings, supported by strong research capabilities through its subsidiary, KGK Science.

KetamineOne Capital Limited (OTC: KONEF) announced significant advancements in its subsidiary, KGK Science, regarding psychedelic research. The company applied for a controlled drugs and substances dealer’s licence to facilitate clinical trials involving various controlled substances, which will enhance KGK's services for third parties. Additionally, Ketamine One completed pre-qualification audits of its Canadian facilities, allowing KGK to conduct clinical trials efficiently. The integration with Aleafia Health is expected to boost their clinical capabilities and access to a diverse patient base.

KetamineOne Capital Limited (KONEF) has reported the ongoing success of the NeuroCatch Platform, a Health Canada-approved Class II medical device, at its Integrated Rehab and Performance clinic in Victoria, BC. NeuroCatch, launched in 2019, offers a rapid 6-minute cognitive assessment, enabling tailored treatment plans for patients, particularly veterans and first responders. As Ketamine One expands to veteran-centric markets, the NeuroCatch Platform is integral to its strategy, enhancing patient outcomes and attracting partnerships with notable institutions like Mayo Clinic.

KetamineOne Capital Limited has appointed Adam Deffett as the Interim CEO following the resignation of former CEO Robert Meister. Effective July 7, 2021, Deffett will also continue his role as VP Capital Markets. The company is initiating a search for a permanent CEO as part of its strategy to become a leader in mental health treatments across North America. KetamineOne operates 16 clinics and aims to consolidate the fragmented industry while enhancing its research capabilities through its contract research division, KGK Science.

KetamineOne Capital Limited (KONEF) announced new engagements with investor relations service providers to enhance its public awareness and investor engagement strategies. CanaComGroup is contracted for a six-month investor awareness program, receiving $50,000 plus GST. CFN Media has a three-month agreement for $27,000, while Proactive Investors will provide services over thirteen months for $25,000 plus GST. Additionally, Ketamine One granted 50,000 stock options at $1.70, with a five-year term. The company aims to lead in mental health treatments with a network of 15 clinics across North America.

KetamineOne Capital Limited (OTC: KONEF) is expanding its mental health platform through strategic initiatives led by KGK Science, its wholly-owned research organization. The company is advancing psychedelic research, reporting a 60% increase in project requests over the past year. KGK has been awarded several contracts, including clinical trials and studies related to novel compounds. Notably, it is collaborating with various clients in psychedelic studies while aiming to integrate vertically within Ketamine One’s clinic network, positioning itself as a leader in this emerging field.

Ketamine One Capital Limited has completed its acquisition of Integrated Rehab and Performance Ltd. (IRP), enhancing its mental health treatment offerings. The acquisition involves 100% of IRP's shares, with CEO Steven Inglefield joining Ketamine One's board. The integration promises to advance treatment for military veterans and first responders using a successful model from IRP, which has conducted 10,000 unique treatments. Ketamine One issued 602,410 shares as consideration, with a structured lockup period for trading.

Ketamine One Capital Limited has appointed Loreto Grimaldi to its Board of Directors, enhancing the company’s governance with over 25 years of experience in corporate law and governance. Grimaldi's background in healthcare and technology positions him as a valuable asset as the company aims to lead in mental health treatments. Ketamine One currently operates 15 clinics across North America and aims to expand further, having recently added KGK Science as its contract research division, positioning itself for growth in the fragmented mental health industry.

Ketamine One Capital Limited has announced an Arrangement Agreement with its subsidiary, Milgauss Investments Ltd. This agreement involves transferring certain assets in exchange for 1,007,729 common shares of SpinCo. Following the transfer, Ketamine One intends to spin out these shares to its shareholders, with no change in their holdings. Each shareholder will receive 1/110 of a Spin-Out Share for each Ketamine One common share held. The transaction requires shareholder and British Columbia Supreme Court approval and aims for listing SpinCo shares on the Canadian Securities Exchange.